Outstanding Recoveries
- Home
- Outstanding Recoveries
Verdicts & Settlements
Since Milberg’s founding in 1965, the firm has recovered more than $50 billion for our clients while prompting meaningful changes in corporate governance.
Filter By
Select Practice Area
-
See More$580+ Million Settlement – Cathode Ray Tube (CRT) Antitrust Litigation
In re Cathode Ray Tube (CRT) Antitrust Litigation, MDL 1917 (U.S. District Court for the Northern District of California)Milberg represented indirect purchaser plaintiffs in this class action alleging an international conspiracy among defendants to keep prices for cathode ray tube (CRT) displays artificially high. Milberg had a significant discovery role in the prosecution of this class action with settlements exceeding $580 million. -
See More$118+ Million Settlement – Disposable Contact Lens Antitrust Litigation
In re Disposable Contact Lens Antitrust Litigation, 3:15-md-02626 (U.S. District Court for the Middle District of Florida)Milberg represented indirect purchasers in a class action alleging that defendants conspired to maintain artificially high prices for disposable contact lenses through policies that prevented resale of the subject contact lenses below a minimum price. Settlements exceeded $118 million. -
See More$460 Million Settlement – Raytheon Co. Securities Litigation
In re Raytheon Co. Securities Litigation, No. 99-12142 (D. Mass.)Milberg served as Lead Counsel in this case, which alleged that a major defense contractor failed to properly write down assets on construction contracts. In 2004, Raytheon and its auditor, PricewaterhouseCoopers LLP, settled for a total of $460 million. -
See More$1 Billion+ Trial Verdict – Vivendi Universal, S.A. Securities Litigation
In re Vivendi Universal, S.A. Securities Litigation, No. 02-CV-5571 (S.D.N.Y.)Milberg was one of two Lead Trial Counsel in this securities fraud case tried to a jury over four months in 2009-2010. The jury found Vivendi liable for dozens of false or misleading statements and awarded damages valued at well over a billion dollars. Six months later, in an unrelated case, the Supreme Court ruled that purchasers on foreign securities exchanges could not recover under U.S. law. Our case against Vivendi continued with post-verdict proceedings under the new standard, and damages have been distributed to U.S. class members totaling over $100 million. -
See More$138 Million Settlement – Biovail Corp. Securities Litigation
In re Biovail Corp. Securities Litigation, No. 03-8917 (S.D.N.Y.)Milberg, representing Local 282 Welfare Trust Fund and serving as Co-Lead Counsel, litigated this securities action alleging that defendants made misleading statements concerning Biovail’s financial results and its drug, Cardizem LA. Following substantial discovery, including depositions across the U.S. and Canada, Milberg obtained a $138 million settlement for the class, and Biovail agreed to institute significant corporate governance changes.
